- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05146934
The Relationship Between Hormone Sensitivity and Imaging of Idiopathic Interstitial Pneumonia by Artificial Intelligence (IIP)
November 23, 2021 updated by: Peking University Third Hospital
Application of artificial intelligence deep learning algorithm to analyze the relationship between hormone sensitivity of idiopathic interstitial pneumonia and imaging features of high resolution CT.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Methods: the medical records and chest high-resolution CT images of patients with idiopathic interstitial pneumonia admitted to the respiratory department of the Third Hospital of Peking University from June 1, 2012 to December 31, 2020 were retrospectively analyzed.Application of artificial intelligence deep learning neural convolution network method to create recognition technology of different imaging features.Including ground glass, mesh, honeycomb, nodule or consolidation, the model was established.
IIP patients were divided into hormone sensitive group and hormone insensitive group according to whether the use of hormone was effective or not.Logistic regression analysis was used to analyze the correlation between statistically significant parameters and hormone sensitivity.Artificial intelligence was used to establish the correlation model between imaging features and clinical data and hormone sensitivity.
Study Type
Observational
Enrollment (Actual)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Peking University Third Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
From June 1, 2012 to December 31, 2020, all inpatients with IIP were admitted to the respiratory and critical care department of the Third Hospital of Peking University.
Total patients are 150, 45 patients using hormone, average age 62 years old, 21 male.
Description
Inclusion Criteria:
Clinical-pathological-radiology diagnosis of idiopathic interstitial pneumonia Hormone therapy was used; The follow-up data were complete, and the effect of hormone use could be judged.
Exclusion Criteria:
Lung infection disease; Heart failure; Connective tissue disease; IIP Without hormone therapy ; IIP but the follow-up data were incomplete, and the effect of hormone use could not be judged.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hormone sensitive group
Prednisone, 0.5mg/kgqd, 3-6months
|
Ground glass,honeycomb,reticulation, consolidation
|
Hormone insensitivity group
Prednisone, 0.5mg/kgqd, 3-6months
|
Ground glass,honeycomb,reticulation, consolidation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
clinical data and imaging feature ratios in both groups
Time Frame: 3-6 months after medication
|
clinical data including ages,gender,symptoms,signs,smoking history,complications,laboratory examination,lung function.
Imaging feature including ground-glass opacity, reticulation, honeycomb and consolidation.
|
3-6 months after medication
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the relationship between imaging feature ratios and hormone sensibility
Time Frame: 3-6 months after medication
|
Logistic regression analyzing the relationship between imaging feature ratios and hormone sensibility.
|
3-6 months after medication
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
development of artificial intelligence algorithm model
Time Frame: 3-6 months after medication
|
The U-net method of deep learning convolutional neural network (CNN) was used to create the recognition model of different imaging features.
Imaging features include ground-glass opacity, reticulation, honeycomb and consolidation.
With the area ratio of imaging features of the two groups as the input and hormone efficacy as the output, the correlation model between imaging features and hormone sensitivity was established by using artificial intelligence k nearest neighbor (KNN) algorithm and support vector machine (SVM) algorithm.
|
3-6 months after medication
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bei He, Peking University Third Hospital Respiratory and critical care department
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 30, 2019
Primary Completion (Actual)
June 1, 2021
Study Completion (Actual)
June 30, 2021
Study Registration Dates
First Submitted
June 30, 2021
First Submitted That Met QC Criteria
November 23, 2021
First Posted (Actual)
December 7, 2021
Study Record Updates
Last Update Posted (Actual)
December 7, 2021
Last Update Submitted That Met QC Criteria
November 23, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LM2019173
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Interstitial Pneumonia
-
Lawson Health Research InstituteRecruitingIdiopathic Pulmonary Fibrosis | Idiopathic Interstitial Pneumonia | Nonspecific Interstitial PneumoniaCanada
-
North East Japan Study GroupBoehringer IngelheimActive, not recruiting
-
National Jewish HealthUniversity of Colorado, Denver; Vanderbilt University; Landspitali University...RecruitingIdiopathic Pulmonary Fibrosis | Idiopathic Interstitial Pneumonia | Familial Pulmonary Fibrosis | Familial Interstitial PneumoniaUnited States, Iceland
-
IRCCS Azienda Ospedaliera Universitaria San Martino...CompletedUsual Interstitial Pneumonia | Nonspecific Interstitial Pneumonia
-
Central Hospital, Nancy, FranceUnknownIdiopathic Interstitial PneumoniaFrance
-
Reata, a wholly owned subsidiary of BiogenCompletedIdiopathic Pulmonary Fibrosis | Pulmonary Arterial Hypertension | Pulmonary Hypertension | Interstitial Lung Disease | Sarcoidosis | Idiopathic Interstitial Pneumonia | Cryptogenic Organizing Pneumonia | Desquamative Interstitial Pneumonia | Respiratory Bronchiolitis Associated Interstitial Lung Disease and other conditionsUnited States, Germany
-
Federal Research Clinical Center of Federal Medical...CompletedIdiopathic Pulmonary Fibrosis | Interstitial Lung Disease | Idiopathic Interstitial PneumoniaRussian Federation
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); Vanderbilt University; National...TerminatedIdiopathic Interstitial PneumoniasUnited States
-
BayerTerminatedIdiopathic Interstitial Pneumonias / Hypertension,PulmonaryBelgium, Israel, Spain, United States, Switzerland, New Zealand, Greece, Portugal, Japan, Argentina, Canada, Denmark, France, Germany, Russian Federation, Turkey, Colombia, Saudi Arabia, Australia, Italy, United Kingdom
-
Andreas GuentherActive, not recruitingIdiopathic Pulmonary Fibrosis | Idiopathic Interstitial Pneumonia | Interstitial Lung Diseases | Diffuse Parenchymal Lung DiseasesUnited Kingdom, Germany, Austria, Italy, France
Clinical Trials on high resolution CT
-
Central Hospital, Nancy, FranceNot yet recruitingOtitis Media | Otosclerosis
-
Assiut UniversityNot yet recruitingInterstitial Lung Disease
-
Central Hospital, Nancy, FranceNot yet recruitingOtosclerosisFrance
-
Radboud University Medical CenterCompletedThe Benefit of UHR-CT: Precision of Repeated Volume Measurements of Pulmonary Nodules (Coffee Break)Pulmonary Nodule, SolitaryNetherlands
-
Central Hospital, Nancy, FranceLorraine Cancer Institute - ICL; Emille Gallé Surgical Center - CCEG; Diagnostic...RecruitingBone Neoplasm | Soft Tissue NeoplasmFrance
-
University of LiegeRecruitingBone Loss | Kidney Transplant; ComplicationsBelgium
-
Cliniques universitaires Saint-Luc- Université...Recruiting
-
Hospices Civils de LyonUnknown
-
University of ParmaUnknownRenal Transplantation | Kidney-pancreas TransplantationItaly